SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is trending as the community rallies around the cryptocurrency. Recent treasury acquisitions are a key talking point, as is the broader enthusiasm around Bitcoin-native culture. Community members express bullish sentiment and highlight the growing $DOG army.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

SLAP is trending as the community rallies around its real-world utility and partnerships, including collaborations with MMA athletes and esports streamers. Active community members are emphasizing that SLAP is more than just a meme and are focused on its global brand development. The project's accessibility on the Base network is also a key point of discussion.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as community members express bullish sentiment and promote its strong community. Conversations highlight the project's ambition to build a lasting movement within the Solana ecosystem, emphasizing a shift in finance. Community members are adding it to watchlists, anticipating a potential move.

an open-source peer-to-peer digital currency

Ocvcoin

Ocvcoin is trending negatively amid community concerns of a potential rug pull and significant bearish sentiment. Traders are highlighting heavy selling pressure, broken support levels, and a lack of buyer interest, contributing to the coin's sharp decline. Discussions suggest a broader market downturn is exacerbating Ocvcoin's challenges.

iShares Bitcoin Trust ETF - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is trending as Bitcoin experiences volatility, sparking debates on market direction. Community discussions range from bearish sentiment, citing potential corrections, to bullish takes emphasizing institutional investment and long-term growth potential, including speculation around a rotation from gold. News catalysts focus on ETF fund flows and potential price targets, with some analysts suggesting a near term drop before further gains.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

SGML is trending amid fluctuating lithium prices and discussion around Q3 earnings, which revealed a net loss. Community chatter focuses on recent insider buying activity and speculation about the company's long-term potential, with some expressing concerns about the stock's volatility and others remaining optimistic about future growth in the lithium sector.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Strike Coin

Starknet ($STRK) is trending due to growing excitement around its BTCFi incentives and surging staking activity, with some community members drawing comparisons to Zcash ($ZEC) because of its co-founder. Discussions also highlight Starknet's potential for scaling Bitcoin and Ethereum, as well as integrating privacy features into Layer 2 solutions. Upgrades to Starknet's technology are reducing transaction costs and enhancing scalability which are key talking points.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPeng is trending amid discussions about its Q3 earnings expectations, potential profitability, and expansion into robotics and flying cars. The community is weighing the company's financial health, revenue growth, and gross margin improvements, while also comparing its technology and valuation to competitors like Tesla. Concerns about Hong Kong price discrepancies and potential dilution are also part of the conversation.

cKES is a stablecoin following a price of fiat currency Kenyan Shilling

Celo Kenyan Shilling

Celo Kenyan Shilling ($CKES) is trending due to community concerns of it being a scam, specifically in relation to $OCV. Discussions revolve around the potential risks and validity of the token.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow With Knife ($CAW) is gaining traction as a multi-chain meme coin on Solana, BSC, CRO, and ETH, with the community highlighting its fully circulated supply and deflationary burn mechanism. There's discussion around its potential to revolutionize volume on the Cronos chain and disrupt Bitcoin's dominance. Community members are using tag phrases like $BROKE $CAW $DOG $SLAP $WAGMI to express their sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$AVXL Here are the types of re-analyses that have historically been the most successful at reversing a negative CHMP opinion during a re-examination. These patterns come from public EMA assessment reports of medicines that ultimately won approval after initially receiving a negative opinion.
✅ 1. Clarifying Statistical Methodology
This is the #1 most successful strategy.
Many initial negative opinions come from:
Misunderstandings of statistical models
Disagreements about missing-data handling
Not clearly justifying multiplicity control or hierarchy
Inconsistent population definitions
Successful re-analyses include:
Re-running analyses using the CHMP-preferred statistical model
Demonstrating robustness across multiple imputation strategies
Providing clearer justification for the analysis hierarchy
Harmonizing ITT and per-protocol definitions
✨ The key: Show that regardless of analytic method, the drug still meets efficacy criteria.

Sharon

Arch Stanton

Nobody

Lilia

Dennis Alles

James Kunkel

Humbert

William Lawson

Jason Romer

sage four

David Lees

Siva Akurati

StockTwits for iOS

Anavex Life Sciences Corp

 Here are the types of re-analyses that have historically been the most successful at reversing a negative CHMP opinion during a re-examination. These patterns come from public EMA assessment reports of medicines that ultimately won approval after initially receiving a negative opinion.
✅ 1. Clarifying Statistical Methodology
This is the #1 most successful strategy.
Many initial negative opinions come from:
Misunderstandings of statistical models
Disagreements about missing-data handling
Not clearly justifying multiplicity control or hierarchy
Inconsistent population definitions
Successful re-analyses include:
Re-running analyses using the CHMP-preferred statistical model
Demonstrating robustness across multiple imputation strategies
Providing clearer justification for the analysis hierarchy
Harmonizing ITT and per-protocol definitions
✨ The key: Show that regardless of analytic method, the drug still meets efficacy criteria.

✅ 2. Re-analyses Focusing on Subpopulations Pre-specified in the Protocol
You cannot introduce new post-hoc groups.
But you can re-analyze pre-specified subgroups, such as:
Mild vs. moderate disease
Biomarker-positive cohorts
Patients with confirmed genetic markers
Patients meeting certain baseline severity thresholds
Why these work:
If the original efficacy signal is diluted by a broad population, showing strong, consistent benefit in the group the drug is intended for can change the CHMP’s view.

coinspitter

Edward H

Bill morrin

#AVXL Improved Benefit–Risk Modeling
This is especially powerful in conditions with high unmet need (e.g., neurology, oncology, rare diseases).
Useful re-analyses:
Quality-adjusted life-year (QALY) modeling
Re-analysis using updated standard-of-care comparators
Sensitivity testing on assumptions used in the benefit–risk model
Sometimes simply reframing the benefit–risk argument using data already submitted can turn the decision around.
🟩 Why these re-analyses work
They do not introduce new clinical data (which is forbidden), but they:
Clarify the evidence
Eliminate misunderstandings
Address methodological concerns
Strengthen the internal consistency of the benefit–risk evaluation
If the CHMP sees that the same dataset, when properly understood, supports efficacy and safety, they can—and often do—reverse their original negative opinion.

 Improved Benefit–Risk Modeling
This is especially powerful in conditions with high unmet need (e.g., neurology, oncology, rare diseases).
Useful re-analyses:
Quality-adjusted life-year (QALY) modeling
Re-analysis using updated standard-of-care comparators
Sensitivity testing on assumptions used in the benefit–risk model
Sometimes simply reframing the benefit–risk argument using data already submitted can turn the decision around.
🟩 Why these re-analyses work
They do not introduce new clinical data (which is forbidden), but they:
Clarify the evidence
Eliminate misunderstandings
Address methodological concerns
Strengthen the internal consistency of the benefit–risk evaluation
If the CHMP sees that the same dataset, when properly understood, supports efficacy and safety, they can—and often do—reverse their original negative opinion.

@homerromer do  you  know  which  subgroup  was  pre-specified  in  the  blarca  trial?

StockTwits Web

 do  you  know  which  subgroup  was  pre-specified  in  the  blarca  trial?